SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.

Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.

Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.